JP2024515885A5 - - Google Patents
Info
- Publication number
- JP2024515885A5 JP2024515885A5 JP2023566921A JP2023566921A JP2024515885A5 JP 2024515885 A5 JP2024515885 A5 JP 2024515885A5 JP 2023566921 A JP2023566921 A JP 2023566921A JP 2023566921 A JP2023566921 A JP 2023566921A JP 2024515885 A5 JP2024515885 A5 JP 2024515885A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- compound
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182207P | 2021-04-30 | 2021-04-30 | |
| US63/182,207 | 2021-04-30 | ||
| PCT/US2022/026898 WO2022232487A1 (en) | 2021-04-30 | 2022-04-29 | Methods for treating and monitoring parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515885A JP2024515885A (ja) | 2024-04-10 |
| JP2024515885A5 true JP2024515885A5 (https=) | 2025-05-09 |
Family
ID=83847331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566921A Pending JP2024515885A (ja) | 2021-04-30 | 2022-04-29 | パーキンソン病を処置及びモニタリングするための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240207266A1 (https=) |
| EP (1) | EP4329763A4 (https=) |
| JP (1) | JP2024515885A (https=) |
| CN (1) | CN117769422A (https=) |
| AU (1) | AU2022267325A1 (https=) |
| CA (1) | CA3217230A1 (https=) |
| MX (1) | MX2023012851A (https=) |
| TW (1) | TW202308635A (https=) |
| WO (1) | WO2022232487A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025051214A1 (zh) * | 2023-09-07 | 2025-03-13 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其制备方法 |
| CN121226329A (zh) * | 2024-06-28 | 2025-12-30 | 成都康弘药业集团股份有限公司 | 一种治疗或预防lrrk2介导的疾病的化合物 |
| CN119119035B (zh) * | 2024-08-30 | 2025-11-04 | 中山大学 | 一种ripk1激酶靶点抑制剂及其制备方法与应用 |
| CN118878521B (zh) * | 2024-09-26 | 2025-02-14 | 苏州美诺医药科技有限公司 | 一种lrrk2抑制剂的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102091895B1 (ko) * | 2012-05-03 | 2020-04-14 | 제넨테크, 인크. | 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체 |
| WO2014059052A1 (en) * | 2012-10-09 | 2014-04-17 | Uab Research Foundation | Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism |
| SMT202100699T1 (it) * | 2016-06-16 | 2022-01-10 | Denali Therapeutics Inc | Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi |
-
2022
- 2022-04-29 JP JP2023566921A patent/JP2024515885A/ja active Pending
- 2022-04-29 TW TW111116487A patent/TW202308635A/zh unknown
- 2022-04-29 US US18/288,734 patent/US20240207266A1/en active Pending
- 2022-04-29 WO PCT/US2022/026898 patent/WO2022232487A1/en not_active Ceased
- 2022-04-29 AU AU2022267325A patent/AU2022267325A1/en active Pending
- 2022-04-29 CN CN202280037732.0A patent/CN117769422A/zh active Pending
- 2022-04-29 EP EP22796791.6A patent/EP4329763A4/en active Pending
- 2022-04-29 MX MX2023012851A patent/MX2023012851A/es unknown
- 2022-04-29 CA CA3217230A patent/CA3217230A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024515885A5 (https=) | ||
| JP5749255B2 (ja) | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 | |
| US6231889B1 (en) | Unit dosage forms for the treatment of herpes simplex | |
| JP6837486B2 (ja) | 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法 | |
| CZ295567B6 (cs) | Tetrahydrolipstatin pro výrobu orálního farmaceutického prostředku pro ošetřování typu II diabetes mellitus | |
| US11931342B2 (en) | Magnesium biotinate compositions and methods of use | |
| CA2453263A1 (en) | Pharmaceutical compositions containing terbinafine and use thereof | |
| US20180353447A1 (en) | Butyrate salts for use in inflammatory diseases | |
| JP2005528430A5 (https=) | ||
| JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
| US20070071815A1 (en) | Oral formulation of creatine derivatives and method of manufacturing same | |
| HU228051B1 (en) | A pharmaceutical composition for the treatment of autoimmune diseases | |
| AU2016402338A1 (en) | Combinational compositions and methods of use thereof | |
| CZ300844B6 (cs) | Lécivo pro lécbu plicní hypertenze | |
| EP0306377A1 (fr) | Nouvelles compositions d'éléments minéraux et/ou oligoéléments et leur procédé de préparation | |
| EP1465607A1 (fr) | Compositions pharmaceutiques a liberation modifiee | |
| US20170296499A1 (en) | Combinational compositions and methods of use thereof | |
| US20060062853A1 (en) | Treating neuromuscular disorders with an oral formulation of creatine derivatives | |
| CA3071096A1 (en) | Co-administration of minocycline and colistin to reduce acute kidney injury | |
| WO2024249509A1 (en) | Sparsentan for use in a method of treating iga-mediated diseases | |
| JP2024084670A5 (https=) | ||
| JP2025535162A (ja) | βアドレナリン作動及びムスカリン拮抗組成物並びに使用方法 | |
| AU2269495A (en) | Use of isosorbide-5-mononitrate | |
| CN119700749A (zh) | 泽漆内酯的医药用途 |